Physician profile
Ananth Krishnan
NPI 1073521902
$2,162.02
in general payments reported to CMS, 2019-2025
24 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $156 · 2021: $152 · 2022: $369 · 2023: $511 · 2024: $258 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $919.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $309.24 | 2019-2024 | Spravato, Xarelto |
| Novo Nordisk INC | $303.42 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $248.49 | 2021-2024 | |
| Abbott Laboratories | $242.85 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $155.83 | 2021-2025 | Krystexxa, Otezla, Repatha |
| Allergan, INC. | $133.94 | 2020 | |
| Phathom Pharmaceuticals, INC. | $116.42 | 2024 | Voquezna |
| Medtronic Vascular, INC. | $105.34 | 2019 | |
| Roche Diagnostics Corporation | $99.87 | 2019 | |
| Boston Scientific Corporation | $85.93 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $78.28 | 2019-2025 | Libtayo |
| Pfizer INC. | $51.73 | 2021-2024 | |
| Kerecis Limited | $37.93 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Biogen, INC. | $27.90 | 2023 | Skyclarys |
| Eisai INC. | $21.92 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $19.60 | 2023 | Monoferric |
| Daiichi Sankyo INC. | $17.50 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.35 | 2022 | |
| Glaxosmithkline, LLC. | $16.03 | 2023 | Trelegy Ellipta, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $15.96 | 2022 | |
| Lilly USA, LLC | $15.03 | 2022 | |
| Genzyme Corporation | $14.97 | 2022 | |
| Merck Sharp & Dohme LLC | $13.74 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ananth Krishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.